Horse tranquilliser trial is awarded $750,000 grant for Parkinson’s research

News

Author: Simge Eva DoganPublished: 26 July 2018

Parkinson's LifePrep: Parkinson's LifeCook: Parkinson's LifeServes:

ketamine

Researchers at the University of Arizona College of Medicine, Tucson, US, will be trialling ketamine – a recreational drug previously used to medicate people with depression – as a treatment for Parkinson’s.

The research – led by Dr Scott Sherman – is being supported with a three-year grant of $750,000 from the Arizona Biomedical Research Commission.

The initial clinical trial will test the effect of ketamine for treating dyskinesia in 10 patients. In addition, the researchers will carry out a separate rodent study to examine how the drug affects the brain.

Dr Scott Sherman, a neurologist at the University of Arizona College of Medicine, said: “Ketamine has been long overlooked. Now it could prove very useful for Parkinson’s patients.”

For information on the latest Parkinson’s research please visit the European Parkinson’s Disease Association website.

For more information on this article click here.

Go Back

Share this story

Comments


Related articles


US actor Alan Alda at the Australian National University

Global update

Alan Alda: Parkinson’s is “not the end of the world”

The US actor shares his experience of diagnosis

READ MORE
MJFF $2 grant

PD in Practice

Fox Foundation offers $2m for ‘game-changing’ Parkinson’s breakthrough

Calling all researchers! $2m prize to develop imaging ‘tracer’ for key

READ MORE
People chatting after exercise

PD in Practice

Your gym or mine: accessing specialised community Parkinson’s exercise programmes

The best exercise regime is one you stick to. Sense, or nonsense?

READ MORE